Toward a better care of cancer by improving immunotherapy.
Developing more effective, long-lasting treatments with minimal side effects.
Teclison is a clinical-stage biotech company focusing on novel cancer therapeutics.
We have developed a revolutionary platform technology that induces tumor into necrosis and converts the cancer into a therapeutic vaccine. Our platform significantly enhances the therapeutic benefit of immunotherapy, and can be leveraged to treat nearly all solid tumors. We have the unique advantage in solving the challenge of immunotherapy in liver metastasis.
Out-licensing development of TEC-001 in China to Hangzhou Raygene Pharmaceutical.
Teclison and Hangzhou Raygene Pharmaceutical signed a licensing agreement, in which Raygene obtains commercial rights in China for TEC-001. Teclison will receive upfront, milestone, and future royalty payments from this collaboration.
Announcing Collaboration with Merck.
Teclison has entered into a clinical collaboration with Merck (known as MSD outside of the US and Canada) on March 2020 to evaluate our therapy in combination with pembrolizumab.
26 Park Street, Suite 100,
Montclair, NJ 07042
10F., No.124, Sec. 2, Nanjing East Road,
Taipei, Taiwan (R.O.C.) 10489